StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Cowen Said FDA Briefing Docs on Biogen (BIIB) Adu 'Not Without Controversy', Citing Statistical Reviewer
November 4, 2020 11:25 AM
Cowen analyst Phil Nadeau said that while the FDA briefing docs on Biogen's (NASDAQ: BIIB) Adu were positive, they were ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Trader Talk